Corporate Alert: GlaxoSmithKline Pakistan Ltd. reports an EPS of 3.22 for the period ended June 30, 2017

Financial Results - For Period Ended

Key Financials

June 30, 2017

June 30, 2016

% Change

Net Sales

3,746,461,774

1,452,239,805

158%

Cost of Sales

2,244,996,000

1,423,435,439

58%

Gross Profit

1,501,465,774

28,804,366

5113%

Selling, Marketing and distribution Expenses

870,515,596

289,849,111

200%

Administrative Expenses

107,357,766

40,412,410

166%

Other Operating Expenses

51,859,553

14,097,824

268%

Other Income

120,310,986

4,363,507

2657%

Operating Profit/(loss)

592,043,845

(311,191,472)

Financial Charges

154,139

70,626

118%

Profit/(loss) before taxation

591,889,706

(311,262,098)

Taxation

284,391,254

90,945,361

213%

Profit/(loss) after taxation

307,498,452

(402,207,459)

EPS - Profit/(loss) per share

3.22

(8.42)